Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice

Wu，Juan1; Hu，Zhidong1; Lu，Shui Hua2; Fan，Xiao Yong1

2022-10-04

10.3389/fmicb.2022.927031

Frontiers in Microbiology   Impact Factor & Quartile

1664-302X

The development of heterologous prime-boost regimens utilizing Bacille Calmette–Guerin (BCG) as the priming vaccine is a promising approach to improve the efficacy of vaccination against tuberculosis (TB). In this study, we examined the ability of a DNA vaccine that expressed a fusion of antigens Rv2299c and Ag85A to boost BCG immunity and protection against Mycobacterium tuberculosis (Mtb) in Balb/c mice. The fusion DNA vaccine was moderately immunogenic and afforded some protection when used on its own. After a priming BCG vaccination, the DNA boost significantly amplified Th1-type cell-mediated immunity compared to that resulting from either BCG or DNA immunization. In the DNA-boosted mice, Ag-specific CD4 and CD8 T cells that were mono-positive for IFN-γ alone were the most prominently expanded in infected lungs. The protective efficacy afforded by BCG against challenge infection was greatly improved by the DNA boost; bacterial loads were significantly reduced in both spleen and lung and histological damage in the lung was less. The use of a DNA vaccine containing the fusion antigens Rv2299c and Ag85A to boost BCG may be a good choice for the rational design of an efficient vaccination strategy against TB.

Bacille Calmette–Guerin DNA vaccine heterologous prime–boost Mycobacterium tuberculosis Rv2299c

SCI

English

Others

[2021YFC2301503] ; [82171815] ; [82171739] ; [81873884] ; [20Y11903400]

Microbiology

Microbiology

WOS:000871304900001

FRONTIERS MEDIA SA

2-s2.0-85139906958

Scopus

1.Shanghai Public Health Clinical Center,Key Laboratory of Medical Molecular Virology of MOE/MOH,Fudan University,Shanghai,China
2.National Medical Center for Infectious Diseases of China Shenzhen Third People Hospital,Southern University of Science and Technology,Shenzhen,China

Wu，Juan,Hu，Zhidong,Lu，Shui Hua,et al. Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice[J]. Frontiers in Microbiology,2022,13.

Wu，Juan,Hu，Zhidong,Lu，Shui Hua,&Fan，Xiao Yong.(2022).Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice.Frontiers in Microbiology,13.

Wu，Juan,et al."Heterologous prime-boost BCG with DNA vaccine expressing fusion antigens Rv2299c and Ag85A improves protective efficacy against Mycobacterium tuberculosis in mice".Frontiers in Microbiology 13(2022).